Brian Ogilvie

Brian Ogilvie is the Vice President of Scientific Consulting at BioIVT, a role held since September 2022. In addition, Ogilvie serves as a Volunteer Assistant Professor at the University of Kansas Medical Center since August 2017. Previously, Ogilvie held various positions at XenoTech from March 1997 to March 2023, including Vice President of Scientific Consulting, Director of Consulting, Principal Scientist, and Senior Scientist, focusing on the interpretation of pre-clinical ADME-tox data, in vitro-in vivo extrapolation (IVIVE), and drug interaction studies in compliance with regulatory standards. Brian Ogilvie earned a Ph.D. in Toxicology from the University of Kansas Medical Center and a B.A. in Molecular Biology from William Jewell College.